Lucid Diagnostics Inc (LUCD) FinancialsLUCDFinancialLucid Diagnostics Inc

Evaluating the bottom line, Lucid Diagnostics Inc maintains a gross margin of -5.16%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -868.45%, while the net margin is -792.88%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively LUCD converts its operational activities into shareholder value.

In the context of the broader market, LUCD competes directly with industry leaders such as PDEX and INCR. With a market capitalization of $184.78M, it holds a significant position in the sector. When comparing efficiency, LUCD's gross margin of -5.16% stands against PDEX's 30.74% and INCR's 30.47%. Such benchmarking helps identify whether Lucid Diagnostics Inc is trading at a premium or discount relative to its financial performance.

Lucid Diagnostics has shown increasing total revenue, with Q2 2026 revenue at 1,474,000 USD, up from 1,263,000 USD in Q1 2026. However, it continues to report significant net losses, with Q2 2026 net income at -14,715,000 USD, reflecting ongoing operational challenges.